GANNET53 targets stabilised mutant p53 in platinum-resistant ovarian cancer
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer.
GANNET53 (Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer) is a FP7 research project funded by the European Commission. The project started in October 2013 and aims at improving prognosis and quality of life in platinum-resistant, p53 mutant ovarian cancer patients. The project is planned for 5.5 years with a funding of 6 million Euros.
Who are we?
GANNET53 is a group of passionate collaborators. Meet the eighteen partners and read how the project is managed.
What we do?
Learn more about our clinical trials and translational research, or start with the project description.
For patients
Patients and relatives find information on ovarian cancer and the trial on the patient website, in four languages.
Press coverage and the events where the project has been presented are collected under Activity; the project office can be reached through the contact page.